期刊
CELLS
卷 11, 期 21, 页码 -出版社
MDPI
DOI: 10.3390/cells11213391
关键词
autoimmunity; B cell; B cell receptor; kinase; receptor; Toll-like receptor; signal transduction; tolerance
类别
资金
- Target2B Consortium
- Dutch Arthritis Foundation [19-1-201]
- Erasmus MC MRace
This review discusses the importance of abnormal B cell signaling in autoimmune diseases, focusing on aberrant B cell receptor (BCR) signaling and other signal transduction pathways. Therapeutic strategies for interfering with B cell signal transduction are also briefly discussed.
Aberrant B cell signaling plays a critical in role in various systemic and organ-specific autoimmune diseases. This is supported by genetic evidence by many functional studies in B cells from patients or specific animal models and by the observed efficacy of small-molecule inhibitors. In this review, we first discuss key signal transduction pathways downstream of the B cell receptor (BCR) that ensure that autoreactive B cells are removed from the repertoire or functionally silenced. We provide an overview of aberrant BCR signaling that is associated with inappropriate B cell repertoire selection and activation or survival of peripheral B cell populations and plasma cells, finally leading to autoantibody formation. Next to BCR signaling, abnormalities in other signal transduction pathways have been implicated in autoimmune disease. These include reduced activity of several phosphates that are downstream of co-inhibitory receptors on B cells and increased levels of BAFF and APRIL, which support survival of B cells and plasma cells. Importantly, pathogenic synergy of the BCR and Toll-like receptors (TLR), which can be activated by endogenous ligands, such as self-nucleic acids, has been shown to enhance autoimmunity. Finally, we will briefly discuss therapeutic strategies for autoimmune disease based on interfering with signal transduction in B cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据